JN.1疫苗接种对JN.1衍生亚型感染的有效性:荷兰前瞻性队列研究
在荷兰前瞻性队列(VASCO)中评估JN.1新冠疫苗接种对SARS-CoV-2感染的有效性。研究期间为2024年9月23日至2025年2月23日,纳入≥60岁及<60岁有医学风险或医护人员。结果显示,<60岁人群疫苗有效性为16%(95%CI:-11-36),≥60岁人群为13%(95%CI:2-23)。JN.1疫苗接种提供的额外保护有限。
要点
- JN.1疫苗对<60岁高风险人群感染有效性16%(95%CI:-11-36),不显著。
- JN.1疫苗对≥60岁人群感染有效性13%(95%CI:2-23),具有统计学意义。
- 对KP.3.1.1和XEC亚型的有效性无显著差异(OR:1.3;95%CI:0.8-2.1)。
核心结论
- 在低发病率5个月研究期间,JN.1疫苗接种对预防SARS-CoV-2感染提供的额外保护有限。
- 观察到的疫苗有效性估计提示对XEC的保护可能低于KP.3.1.1,但检测这种差异的把握度较低。
研究设计与样本
- 前瞻性队列研究(VASCO),纳入JN.1疫苗符合条件者:≥60岁人群及<60岁有医学风险条件或医护人员。
- 通过问卷和血清学定期收集数据,提供自测;感染基于自测阳性报告和/或抗核蛋白血清学结果。
- 感染亚型通过阳性自测样本全基因组测序确定。
主要发现
- 共发生2142例感染,其中72%为自报。
- <60岁符合条件者4490人中1283人(29%)接种疫苗;≥60岁19349人中14400人(74%)接种疫苗。
- <60岁人群疫苗有效性为16%(95%CI:-11-36);≥60岁人群为13%(95%CI:2-23)。
- 针对KP.3.1.1(n=251;27%)的疫苗有效性与针对XEC(n=195;5%)无显著差异(OR:1.3;95%CI:0.8-2.1)。
临床怎么用
- 对于≥60岁人群,JN.1疫苗接种对感染有小幅但具有统计学意义的保护效果(VE 13%)。
- 对于<60岁高风险人群,疫苗对感染的保护效果不显著,决策需结合个体风险与获益。
局限性
- 研究期间发病率低。
- 检测XEC与KP.3.1.1之间疫苗有效性差异的把握度较低。
- 感染多数基于自报自测结果(72%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We estimated vaccine effectiveness (VE) of JN.1 COVID-19 vaccination against SARS-CoV-2 infection by (sub)variant between 23 September 2024 and 23 February 2025. METHODS: JN.1 vaccine-eligible participants of an ongoing prospective cohort study (VAccine Study COvid-19; VASCO) were included: individuals aged ≥60 years, and individuals aged <60 years with a medical risk condition or who were healthcare workers. In VASCO, questionnaire and serology data are regularly collected and self-tests are provided. SARS-CoV-2 infection was based on reported positive self-tests and/or anti-nucleoprotein serology results. The variant of infection was determined by whole genome sequencing of viral genetic material in positive self-tests. VE against infection was estimated using Cox regression with JN.1-vaccination as time-varying exposure, and VE against JN.1 subvariants KP.3.1.1 and XEC using multinomial logistic regression with matching of infected and uninfected participants by calendar week. Models were adjusted for age group, sex, education level, medical risk condition and SARS-CoV-2 infection history. RESULTS: Of 4490 JN.1-vaccine eligible participants <60 years, 1283 (29%) were vaccinated. Of 19,349 participants ≥60 years, 14,400 (74%) were vaccinated. During follow-up 2142 infections occurred, of which the majority was self-reported (72%). VE was 16% (95%CI: -11-36) in participants <60 years and 13% (95%CI: 2-23) in participants ≥60 years. VE against KP.3.1.1 (n = 251;27%) did not differ significantly from the VE against XEC (n = 195;5%)(OR:1.3; 0.8-2.1). CONCLUSION: We found that, during a 5-month study period with low incidence, JN.1-vaccination provided limited added protection in preventing SARS-CoV-2 infection. The observed VE estimates indicate potentially lower protection against XEC than KP.3.1.1, but the power to detect such a difference was low.
引用
- Huiberts AJ, Eggink D, de Gier B, et al. Effectiveness of Omicron JN.1 vaccination against infection with JN.1-derived SARS-CoV-2 subvariants in a prospective cohort study in the Netherlands. Vaccine. 2026. PMID: 42585808. doi:10.1016/j.vaccine.2026.129030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。